Press release
Insmed To Showcase New ARIKAYCE® (amikacin liposome inhalation suspension) And Pipeline Data At American Thoracic Society International Conference
BRIDGEWATER, N.J., April 1, 2019 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of
About this update from Insmed Incorporated
[{"type":"text","content":"BRIDGEWATER, N.J., April 1, 2019 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that new Phase 3 data for ARIKAYCE® (amikacin liposome inhalation suspension) in Mycobacterium avium complex (MAC) lung disease will be presented as a late-breaker at the American Thoracic Society (ATS) International Conference, May 17-22, in Dallas. Additional data on ARIKAYCE as well as on Insmed's pipeline candidates will also be presented at the meeting.\nPresentations include:\nLate-breaker oral session, Monday, May 20, 11:00-11:15 AM CT: A7359 – Sustainability and Durability of Culture Conversion in Patients Receiving Amikacin Liposome Inhalation Suspension (ALIS) for Treatment-Refractory Mycobacterium avium Complex Lung Disease (MAC-LD) in the CONVERT StudyOral session, Monday, May 20, 10:15-10:30 AM CT: A2654 – Pharmacokinetic (PK) Evaluation of Amikacin Liposome Inhalation Suspension (ALIS) in Patients with Treatment-Refractory Nontuberculous Mycobacterial (NTM) Lung Disease Oral session, Monday, May 20, 10:00-10:15 AM CT: A2653 – Open-Label Trial of Amikacin Liposome Inhalation Suspension in M. Abscessus Lung Disease (Insmed-supported investigator-initiated research)Poster presentation, Tuesday, May 21, 11:15 AM-1:00 PM CT; A5049 / P1120 – Pain Assessment After Intraplantar Injection of a Remodulin Equivalent Formulation and Subcutaneous Injection of Treprostinil in RatsPoster presentation, Tuesday, May 21, 11:15 AM-1:00 PM; CT A5055 / P1129 – Determination of the Prostanoid Receptor Subtypes Involved in Treprostinil-Induced Relaxation of Rat Pulmonary Arteries with Intact and Denuded EndotheliumAbout MAC Lung Disease\nMycobacterium avium complex (MAC) lung disease is a rare and serious disorder that can significantly increase morbidity and mortality. Patients with MAC lung disease can experience a range of symptoms that often worsen over time, including chronic cough, dyspnea, fatigue, fever, weight loss, and chest pain. In some cases, MAC lung disease can cause severe, even permanent damage to the lungs, and can be fatal.\nMAC lung disease is an emerging public health concern worldwide with significant unmet need. Current guideline-based treatment involves the use of multi-drug regimens that are not specif...